Targeting RSK1 and RSK2 in TNBC has been shown to result in a reduction in tumor growth both in vitro and in murine models45,46 and RSK inhibitors such as PMD-026 are currently in clinical trials for metastatic TNBC (NCT04115306). This evidence concerns the gene RPS6KA1 and neoplasm.